Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study
- PDF / 1,297,433 Bytes
- 16 Pages / 595.276 x 790.866 pts Page_size
- 56 Downloads / 185 Views
ORIGINAL RESEARCH
Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study Laila Carolina Abu Esba
. Rahaf Ali Alqahtani . Abin Thomas .
Nour Shamas . Lolowa Alswaidan . Gahdah Mardawi
Received: September 17, 2020 / Accepted: October 19, 2020 Ó The Author(s) 2020
L. C. Abu Esba R. A. Alqahtani N. Shamas L. Alswaidan G. Mardawi College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
nonsteroidal anti-inflammatory drugs (NSAIDs) with worse COVID-19 outcomes. Methods: We did a prospective cohort study between April 12 and June 1, 2020. Adults consecutively diagnosed with COVID-19 were included. Information on NSAID use was collected through a telephone questionnaire, and patients were followed up for COVID-19 infection outcomes, including death, admission, severity, time to clinical improvement, oxygen requirement and length of stay. Results: Acute use of ibuprofen was not associated with a greater risk of mortality relative to non-use (adjusted hazard ratio [HR] 0.632 [95% CI 0.073–5.441; P = 0.6758]). Chronic NSAID use was also not associated with a greater risk of mortality (adjusted HR 0.492 [95% CI 0.178–1.362; P = 0.1721]). Acute ibuprofen use was not associated with a higher risk of admission compared to non-NSAID users (adjusted odds ratio OR 1.271; 95% CI 0.548–2.953). NSAID users did not have a significantly longer time to clinical improvement or length of stay. Conclusion: Acute or chronic use of ibuprofen and other NSAIDs was not associated with worse COVID-19 disease outcomes.
A. Thomas College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK
Keywords: COVID-19; COVID-19 outcomes; Ibuprofen; NSAIDs
ABSTRACT Introduction: Ibuprofen disappeared from the pharmacy shelves during the 2019 coronavirus (COVID-19) pandemic. However, a while later, information circulated that ibuprofen should be avoided as it could worsen COVID-19 symptoms. The aim of our study was to assess the association of acute and chronic use of Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40121020-00363-w) contains supplementary material, which is available to authorized users. L. C. Abu Esba (&) R. A. Alqahtani L. Alswaidan G. Mardawi Pharmaceutical Care Department, Ministry of the National Guard, Health Affairs, Riyadh, Saudi Arabia e-mail: [email protected] L. C. Abu Esba R. A. Alqahtani N. Shamas L. Alswaidan G. Mardawi King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
N. Shamas Infection Prevention and Control Department, Ministry of the National Guard, Health Affairs, Riyadh, Saudi Arabia
Infect Dis Ther
INTRODUCTION Key Summary Points Why carry out this study? The concern about ibuprofen and NSAID use circulating in the media during the COVID-19 outbreak was based solely on anecdotal observation, and a correspondence published in the Lancet posed the theoretical explanation that, due to the port of entry
Data Loading...
